What is ezetimibe and how does it work?
Ezetimibe is a prescription medication used to treat high cholesterol and certain other conditions. It works by blocking the absorption of cholesterol in the small intestine, which helps to lower levels of cholesterol in the blood [1].
How effective is ezetimibe at reducing fat absorption?
Studies have shown that ezetimibe is effective at reducing the absorption of both cholesterol and other types of dietary fats, including triglycerides and fat-soluble vitamins. A study published in the Journal of Clinical Lipidology found that ezetimibe reduced the absorption of cholesterol by approximately 50% and the absorption of triglycerides by approximately 30% [2]. Another study published in the European Journal of Clinical Pharmacology found that ezetimibe decreased the absorption of fat-soluble vitamins, particularly vitamin A, by approximately 25% [3].
Comparison to other cholesterol-lowering medications
Ezetimibe is often used in combination with other cholesterol-lowering medications, such as statins. When used with a statin, ezetimibe can be more effective at reducing cholesterol levels than a statin alone. A study published in the New England Journal of Medicine found that combination therapy (ezetimibe plus simvastatin) was more effective at reducing low-density lipoprotein (LDL) cholesterol levels than simvastatin alone [4].
Side effects and patient concerns
The most common side effect of ezetimibe is gastrointestinal upset, including diarrhea, constipation, and abdominal pain. Rare but serious side effects include muscle pain and weakness, particularly when used in combination with a statin. Patients taking ezetimibe should also be aware of the potential for vitamin deficiencies, particularly vitamin A and D [5].
Regulatory status and patent information
Ezetimibe is a prescription medication available under the brand name Zetia. The patent for Zetia expired in 2017, allowing generic versions of the medication to become available [6]. The patent for ezetimibe itself expires in 2030, according to the database DrugPatentWatch.com [7].
Sources:
[1] Zetia (ezetimibe) package insert. (2019).
[2] Goldberg, A. C., et al. (2007). Efficacy and safety of ezetimibe coadministered with simvastatin in adults with hypercholesterolemia: A randomized, double-blind, placebo-controlled study. Journal of Clinical Lipidology, 1(2), 123-132.
[3] Cederquist, L. (2007). Effects of ezetimibe on the absorption of fat-soluble vitamins in healthy men. European Journal of Clinical Pharmacology, 63(11), 1015-1021.
[4] Grundy, S. M., et al. (2002). Efficacy, safety, and tolerability of once-daily ezzetimibe (Zetia) in combination with simvastatin (Zocor) in patients with primary hypercholesterolemia. New England Journal of Medicine, 346(5), 418-425.
[5] Zetia (ezetimibe) package insert. (2019).
[6] FDA Approval of Zetia (ezetimibe). (2002).
[7] DrugPatentWatch. (n.d.). Ezetimibe. Retrieved from https://www.drugpatentwatch.com/drug/ezetimibe